Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma.

"Conflict of Interest Statement Hong Jae Chon has a consulting or advisory role at Eisai, Roche, Bayer, ONO, MSD, BMS, Celgene, Sanofi, Servier, AstraZeneca, SillaJen, Menarini, and GreenCross Cell and has received research grants from Roche, Dong-A ST, and Boryung Pharmaceuticals. Chan Kim has a consulting or advisory role at Roche, ONO, MSD, BMS, Oncocross, and Virocure and has received research grants from Boryung Pharmaceuticals, Oncocross, SillaJen, and Virocure. Ho Yeong Lim has a consulting or advisory role at Eisai, Roche, Bayer, ONO, MSD, BMS, and AstraZeneca. Vincent E. Gaillard is a full-time employee of F. Hoffmann-La Roche Ltd. The other authors have no potential conflicts of interest to disclose."

"This work was supported by the National Research Foundation of Korea [NRF] grants funded by the Korean government [MSIT] [NRF-2023R1A2C2004339 to Hong Jae Chon, NRF-2023R1A2C2006375 to Chan Kim, and NRF-2020R1C1C1003924 to Young Shin Song]."